Development of thermosensitive resiquimod-loaded liposomes for enhanced cancer immunotherapy

Resiquimod (R848) is a toll-like receptor 7 and 8 (TLR7/8) agonist with potent antitumor and immunostimulatory activity. However, systemic delivery of R848 is poorly tolerated because of its poor solubility in water and systemic immune activation. In order to address these limitations, we developed...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Control Release
Glavni autori: Zhang, Hua, Tang, Wei-Lun, Kheirolomoom, Azadeh, Fite, Brett Z, Wu, Bo, Lau, Kenneth, Baikoghli, Mo, Raie, Marina Nura, Tumbale, Spencer K., Foiret, Josquin, Ingham, Elizabeth S., Mahakian, Lisa M., Tam, Sarah M., Cheng, R. Holland, Borowsky, Alexander D., Ferrara, Katherine W.
Format: Artigo
Jezik:Inglês
Izdano: 2020
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7906914/
https://ncbi.nlm.nih.gov/pubmed/33189786
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jconrel.2020.11.013
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items